Skip to Main Content

WASHINGTON — Back in 2019, when the Senate Finance Committee called seven drug industry executives to testify, it seemed like proof that Washington was within striking distance of actually reining in the industry’s high prices.

“It’s past time to get beyond the excuses and make prescription drugs affordable,” Sen. Ron Wyden of Oregon, the top Democrat on the committee, told drugmakers that day.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment